Identification
- Generic Name
- Fluorodopa (18F)
- DrugBank Accession Number
- DB13848
- Background
Fluorodopa F 18 is a fluorinated analog of levodopa used as a diagnostic agent for positron emission tomography (PET) in the evaluation of Parkinsonian syndromes.1 Fluorodopa F 18 PET is used adjunctly with other diagnostic investigations and serves primarily to visualize dopaminergic nerve terminals in the striatum.1
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
Structure for Fluorodopa (18F) (DB13848)
- Weight
- Average: 214.183
Monoisotopic: 214.061920473 - Chemical Formula
- C9H10FNO4
- Synonyms
- 6-Fluoro-(18F)-L-3,4-Dihydroxyphenylalanine
- Fluorodopa (18F)
- Fluorodopa F-18
- L-3,4-Dihydroxy-6-[18F]Fluorophenylalanine
Pharmacology
- Indication
Fluorodopa F 18 is indicated for use with positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS).1
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Fluorodopa F 18 is decarboxylated by aromatic amino acid decarboxylase (AADC) in the striatum to fluorodopamine F 18. Fluorodopamine F 18 is then further metabolized by monoamine oxidase (MAO) to yield [18F] 6-fluoro-3,4-dihydroxyphenylacetic acid, then subsequently by COMT to yield [18F]6-fluorohomovanillic acid.1
Hover over products below to view reaction partners
- Route of elimination
Approximately 80% of the administered radioactivity is eliminated in the urine.1
- Half-life
The plasma half-life following intravenous administration is approximately 1-3 hours.1
- Clearance
The agent is cleared from blood and tissue within 24 hours following administration.1
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareBenserazide The bioavailability of Fluorodopa (18F) can be increased when combined with Benserazide. Carbidopa The bioavailability of Fluorodopa (18F) can be increased when combined with Carbidopa. Methyldopa The bioavailability of Fluorodopa (18F) can be increased when combined with Methyldopa. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Take on an empty stomach. Before fluorodopa F18 administration do not eat or drink anything, except for water, for at least 4 hours.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Fluorodopa F18 Injection 8.33 mCi/1mL Intravenous THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 2019-10-10 Not applicable US 
Fluorodopa F18 Injection 40 mCi/1mL Intravenous THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 2019-10-10 Not applicable US
Categories
- ATC Codes
- V09IX05 — Fluorodopa (18f)
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as tyrosine and derivatives. These are compounds containing tyrosine or a derivative thereof resulting from reaction of tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Tyrosine and derivatives
- Alternative Parents
- Phenylalanine and derivatives / Phenylpropanoic acids / Amphetamines and derivatives / L-alpha-amino acids / P-fluorophenols / M-fluorophenols / Catechols / 1-hydroxy-2-unsubstituted benzenoids / Aralkylamines / Fluorobenzenes show 10 more
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / 3-fluorophenol / 3-halophenol / 3-phenylpropanoic-acid / 4-fluorophenol / 4-halophenol / Alpha-amino acid / Amine / Amino acid / Amphetamine or derivatives show 27 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- 6-fluoro-L-dopa, fluorine-18 radiopharmaceutical (CHEBI:49166)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 2C598205QX
- CAS number
- 92812-82-3
- InChI Key
- PAXWQORCRCBOCU-RPDRGXCHSA-N
- InChI
- InChI=1S/C9H10FNO4/c10-5-3-8(13)7(12)2-4(5)1-6(11)9(14)15/h2-3,6,12-13H,1,11H2,(H,14,15)/t6-/m0/s1/i10-1
- IUPAC Name
- (2S)-2-amino-3-[2-(¹⁸F)fluoro-4,5-dihydroxyphenyl]propanoic acid
- SMILES
- N[C@@H](CC1=CC(O)=C(O)C=C1[18F])C(O)=O
References
- General References
- FDA Approved Drug Products: Fluorodopa F18 injection for intravenous use [Link]
- External Links
- Human Metabolome Database
- HMDB0304885
- ChemSpider
- 50970
- 2571853
- ChEBI
- 49166
- ChEMBL
- CHEMBL3400972
- ZINC
- ZINC000100079068
- Wikipedia
- Fluorodopa
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Recruiting Treatment High Grade Glioma: Glioblastoma (GBM) 1 Not Available Recruiting Not Available Recurrent Soft Tissue Sarcoma / Resectable Soft Tissue Sarcoma / Soft Tissue Sarcoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Parenteral Injection, solution Parenteral 90 MBQ/ML Injection Intravenous 40 mCi/1mL Injection Intravenous 8.33 mCi/1mL Solution, concentrate Parenteral 0.3 GBq Injection, solution Parenteral 0.3 Gbq Injection, solution Parenteral 222 MBQ/ML - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.39 mg/mL ALOGPS logP -2 ALOGPS logP -1.6 Chemaxon logS -2 ALOGPS pKa (Strongest Acidic) 1.32 Chemaxon pKa (Strongest Basic) 9.4 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 103.78 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 49.29 m3·mol-1 Chemaxon Polarizability 19.09 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Pyridoxal phosphate binding
- Specific Function
- Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine, L-5-hydroxytryptophan to serotonin and L-tryptophan to tryptamine.
- Gene Name
- DDC
- Uniprot ID
- P20711
- Uniprot Name
- Aromatic-L-amino-acid decarboxylase
- Molecular Weight
- 53925.815 Da
References
- FDA Approved Drug Products: Fluorodopa F18 injection for intravenous use [Link]
Drug created at June 23, 2017 20:49 / Updated at April 20, 2023 07:02